All dosing regimens were well-tolerated across the Phase 1 clinical study High local exposure to AGMB-129 in the ileum No clinically relevant systemic exposure to AGMB-129, confirming
Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors Funding will support next stage of clinical and corporate development
Agomab Therapeutics NV ('Agomab') today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference
Agomab Therapeutics NV ('Agomab') today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.
Acquisition strengthens Agomab as a leader in targeting growth factor pathways Origo brings TGF-ß-targeted approach with clinical-stage program in Crohn's disease and preclinical candidate